| | |
| Facebook peer groups may be useful for HIV education Monday, Sep 02, 2013 02:04 PM PDT  By Andrew M. Seaman NEW YORK (Reuters Health) - Groups on the popular networking site Facebook may help educate men about HIV prevention and testing, a new study suggests. Researchers found that specially-created Facebook social media groups helped encourage men who have sex with men to reach out for information about testing themselves at home for HIV. ... Full Story | Top |
| Italian poultry worker tests positive for avian flu Monday, Sep 02, 2013 10:29 AM PDT ROME (Reuters) - A man who works with poultry in Italy has tested positive for avian influenza following outbreaks among birds on farms in the northern Emilia Romagna region, the Italian Health Ministry said on Monday. Italian authorities have been culling thousands of birds since the discovery of the H7N7 strain on several farms in August, the first outbreaks of highly pathogenic avian influenza (HPAI) in Italian poultry since 2000. The Ministry said the affected man, who was exposed to sick poultry during work in contaminated areas, has contracted conjunctivitis as a result of his infection. ... Full Story | Top |
| British cost watchdog recommends Thrombogenics eye drug Monday, Sep 02, 2013 09:00 AM PDT BRUSSELS (Reuters) - Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE. Jetrea, which treats vitreomacular adhesion, an ageing-related vision problem that can lead to blindness, was recommended for full reimbursement, also for those patients with early stage symptoms, Thrombogenics said. (Reporting by Robert-Jan Bartunek) Full Story | Top |
| Hospital to home focus may reduce readmissions: study Monday, Sep 02, 2013 06:32 AM PDT By Andrew M. Seaman NEW YORK (Reuters Health) - Helping people who were recently released from a hospital understand how to care for themselves and informing their primary care doctors about their stay may reduce their risk of being admitted back into the hospital, says a new study. Researchers found that implementing a statewide transitional care program for North Carolinians on Medicaid - the state and federal insurance for the poor - was linked to a 20 percent reduction in patients' risk of going back to the hospital during the next year. ... Full Story | Top |
| Novartis heart failure drug effective across patient groups Monday, Sep 02, 2013 05:00 AM PDT By Ben Hirschler AMSTERDAM (Reuters) - An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed. The drug, serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is viewed as an important medicine in the Swiss drugmaker's developmental pipeline. Analysts at Jefferies expect the drug to generate peak sales of $1.5 billion a year. ... Full Story | Top |
| HEMP Party has high ambitions in Australian election Monday, Sep 02, 2013 03:18 AM PDT  SYDNEY (Reuters) - Australia's HEMP Party formally launched its election campaign on Monday with a call for cannabis to be legalized for personal and medical use, just as it is now for industrial purposes. Members of HEMP - Help End Marijuana Prohibition - inflated a 10-meter (33-foot) plastic replica of a joint outside the state police commissioner's office in Sydney and said Australia's jails were overflowing with people criminalized for no good reason. "America has given us huge encouragement," said HEMP president Michael Balderstone. ... Full Story | Top |
| Doctors get good and bad safety news on diabetes drugs Monday, Sep 02, 2013 02:53 AM PDT By Ben Hirschler AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately. Reassuringly, the medicines were not associated with increased rates of either inflammation of the pancreas or cancer - something that has been a worry in the past. However, in the case of AstraZeneca and Bristol-Myers Squibb's approved drug Onglyza, there was a small increase in hospitalizations for heart failure. ... Full Story | Top |
| Not your grandmother's gym class Monday, Sep 02, 2013 01:15 AM PDT By Dorene Internicola NEW YORK (Reuters) - Physical education in the United States has come a long way since the one-size-fits-all regimen of jumping jacks and rope climbing that was the bane of the baby boomer generation. Today, where children learn can determine the type of fitness lessons they receive. ... Full Story | Top |
| Lundbeck appeals against EU Commission fine Sunday, Sep 01, 2013 11:16 PM PDT COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck has filed an appeal against a 93.8 million euros ($123.7 million) fine by the European Commission for deals with rivals to block the supply of generic versions of its citalopra anti-depressant to the market. Lundbeck said in a statement that the aim of the appeal was to have the decision annulled or the fine reduced. The company said it expects a decision on the appeal within two to three years. ($1 = 0.7584 euros) (Reporting by Copenhagen Newsroom; Editing by David Goodman) Full Story | Top |
| New formulation of Roche's Herceptin wins EU approval Sunday, Sep 01, 2013 10:17 PM PDT ZURICH (Reuters) - Swiss drugmaker Roche said on Monday the European Commission had approved a new formulation of its breast cancer drug Herceptin which allows the medicine to be administered more quickly. Roche said it had won approval for a new injectable version of Herceptin which cuts down treatment time to just two to five minutes. It currently takes between 30 to 90 minutes to administer the drug intravenously. ... Full Story | Top |
| Parents' ADHD goals tied to treatment choices: study Sunday, Sep 01, 2013 09:39 PM PDT By Genevra Pittman NEW YORK (Reuters Health) - Parents' goals and concerns for their children with attention-deficit/hyperactivity disorder may influence their decision to start behavior therapy or medication, according to a new study that researchers say supports a shared decision-making approach to ADHD treatment. Researchers found parents who were focused on their child's academic achievement were twice as likely to have the child started on medications, which include Adderall and Ritalin, as other parents. ... Full Story | Top |
|
No comments:
Post a Comment